Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Healthy
Interventions: PF-05230907, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alzheimer Disease
Interventions: BMS-708163, Placebo, Moxifloxacin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Chronic Pain, Nociceptive Pain
Interventions: CNTX-6970, Placebo; Drug · Other
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteers
Interventions: E2730, E2730-matched placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions: Calmangafodipir, Placebo; Drug
Lead sponsor: Egetis Therapeutics AB (publ); Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Influenza
Interventions: Placebo, Favipiravir; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Graft-versus-host Disease (cGVHD)
Interventions: AMG 592, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Healthy Volunteer
Interventions: AZD7268, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Smallpox
Interventions: IMVAMUNE®, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 4,005 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 34
States / cities: Birmingham, Alabama • Anaheim, California • Los Angeles, California + 31 more

Conditions: Influenza
Interventions: Flufirvitide-3 0.05 mg single dose, Flufirvitide-3, 0.1 mg single dose, Flufirvitide-3, 0.2 mg single dose, Flufirvitide-3, 0.4 mg single dose, Placebo; Drug · Other
Lead sponsor: Autoimmune Technologies, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Typhoid Fever
Interventions: Ty800 (Salmonella typhi) Oral Vaccine; Biological
Lead sponsor: Avant Immunotherapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more

Conditions: Healthy Subjects
Interventions: CDX-0159, Normal saline; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Subjects
Interventions: ASP5354, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: SD-101, placebo; Drug
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteer
Interventions: PHP-303, Placebo; Drug · Other
Lead sponsor: pH Pharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obesity
Interventions: NO-13065, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Factory, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Alzheimer's Disease
Interventions: Velusetrag, Placebo; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Healthy Volunteers
Interventions: PRTX-100 (Staphylococcal protein A); Biological
Lead sponsor: Protalex, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BBT-877, Single dose, Placebo group, BBT-877, Multiple doses; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: ABBV-CLS-7262, Placebo, Moxifloxacin 400mg; Drug
Lead sponsor: Calico Life Sciences LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Thrombosis
Interventions: BMS-986141, Placebo, Aspirin, Itraconazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Cypress, California • Austin, Texas

Conditions: Healthy Volunteers
Interventions: LAD603, Placebo; Drug · Other
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: PF-04895162, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Coronary Artery Disease
Interventions: RespirAct; Device
Lead sponsor: Indiana University; Other
Eligibility: 45 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Single Dose Study of PF-05230907 in Healthy Japanese Subjects

Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects

A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects

A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants

SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza

A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants

Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

A Phase 1 Study of CDX-0159

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

A Study of Safety, Tolerability, and Pharmacokinetics of Single Doses of PHP-303 in Healthy Subjects

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects

A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162

Needle Free Assessment of Myocardial Oxygenation in Healthy Subjects